ASR Vermogensbeheer N.V. Boosts Stock Holdings in McKesson Corporation $MCK

ASR Vermogensbeheer N.V. raised its stake in McKesson Corporation (NYSE:MCK) by 9.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 17,303 shares of the company’s stock after acquiring an additional 1,453 shares during the period. ASR Vermogensbeheer N.V.’s holdings in McKesson were worth $13,367,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in MCK. IAM Advisory LLC lifted its position in shares of McKesson by 0.3% during the third quarter. IAM Advisory LLC now owns 3,908 shares of the company’s stock worth $3,019,000 after purchasing an additional 13 shares during the last quarter. PDS Planning Inc grew its holdings in shares of McKesson by 1.1% in the third quarter. PDS Planning Inc now owns 1,209 shares of the company’s stock worth $934,000 after purchasing an additional 13 shares during the last quarter. Cardinal Point Capital Management ULC increased its stake in McKesson by 2.2% in the 2nd quarter. Cardinal Point Capital Management ULC now owns 645 shares of the company’s stock worth $473,000 after buying an additional 14 shares during the period. Goldstein Advisors LLC boosted its position in McKesson by 4.4% in the 3rd quarter. Goldstein Advisors LLC now owns 334 shares of the company’s stock valued at $258,000 after buying an additional 14 shares during the period. Finally, Cypress Wealth Services LLC grew its stake in McKesson by 3.7% in the 2nd quarter. Cypress Wealth Services LLC now owns 417 shares of the company’s stock worth $305,000 after acquiring an additional 15 shares in the last quarter. Hedge funds and other institutional investors own 85.07% of the company’s stock.

Insider Buying and Selling at McKesson

In other McKesson news, CAO Napoleon B. Rutledge, Jr. sold 329 shares of McKesson stock in a transaction on Friday, November 7th. The shares were sold at an average price of $861.63, for a total value of $283,476.27. Following the completion of the transaction, the chief accounting officer owned 328 shares of the company’s stock, valued at approximately $282,614.64. The trade was a 50.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Thomas L. Rodgers sold 276 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $816.18, for a total transaction of $225,265.68. Following the completion of the transaction, the executive vice president owned 2,268 shares of the company’s stock, valued at approximately $1,851,096.24. This trade represents a 10.85% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.08% of the stock is currently owned by company insiders.

McKesson Stock Down 0.5%

Shares of MCK stock opened at $840.29 on Friday. McKesson Corporation has a 52-week low of $570.51 and a 52-week high of $895.58. The stock has a market cap of $103.72 billion, a PE ratio of 26.15, a price-to-earnings-growth ratio of 1.38 and a beta of 0.41. The business has a 50-day simple moving average of $833.47 and a 200-day simple moving average of $766.45.

McKesson (NYSE:MCK) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $9.86 earnings per share for the quarter, beating the consensus estimate of $8.84 by $1.02. McKesson had a negative return on equity of 248.14% and a net margin of 1.04%.The company had revenue of $103.15 billion during the quarter, compared to analysts’ expectations of $103.80 billion. During the same period last year, the business earned $7.07 earnings per share. McKesson’s quarterly revenue was up 10.2% on a year-over-year basis. Sell-side analysts anticipate that McKesson Corporation will post 32.77 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 2nd. Investors of record on Monday, December 1st were paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. The ex-dividend date was Monday, December 1st. McKesson’s payout ratio is currently 10.21%.

Analyst Ratings Changes

MCK has been the subject of a number of research reports. Weiss Ratings reiterated a “buy (a-)” rating on shares of McKesson in a report on Monday, December 29th. Wells Fargo & Company upped their target price on McKesson from $816.00 to $914.00 and gave the stock an “equal weight” rating in a report on Monday, November 10th. Wall Street Zen downgraded McKesson from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Morgan Stanley lifted their price objective on McKesson from $857.00 to $916.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Finally, UBS Group boosted their price target on shares of McKesson from $920.00 to $980.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $895.79.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.